These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 8557344)

  • 41. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of
    Turbyfill KR; Clarkson KA; Vortherms AR; Oaks EV; Kaminski RW
    mSphere; 2018; 3(2):. PubMed ID: 29600284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains.
    Hartman AB; Powell CJ; Schultz CL; Oaks EV; Eckels KH
    Infect Immun; 1991 Nov; 59(11):4075-83. PubMed ID: 1937767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.
    Tobias J; Lebens M; Bölin I; Wiklund G; Svennerholm AM
    Vaccine; 2008 Feb; 26(6):743-52. PubMed ID: 18191006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral shigella vaccines.
    Hale TL; Formal SB
    Curr Top Microbiol Immunol; 1989; 146():205-11. PubMed ID: 2659269
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Orr N; Robin G; Cohen D; Arnon R; Lowell GH
    Infect Immun; 1993 Jun; 61(6):2390-5. PubMed ID: 8500877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategy for cross-protection among Shigella flexneri serotypes.
    Noriega FR; Liao FM; Maneval DR; Ren S; Formal SB; Levine MM
    Infect Immun; 1999 Feb; 67(2):782-8. PubMed ID: 9916090
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Vaccination against the enterobacteria responsible for enteric infections].
    Sansonetti PJ
    Ann Gastroenterol Hepatol (Paris); 1994; 30(2):60-3. PubMed ID: 8210205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of strain viability and antigen dose on the use of attenuated mutants of Salmonella as vaccine carriers.
    Cárdenas L; Dasgupta U; Clements JD
    Vaccine; 1994 Jul; 12(9):833-40. PubMed ID: 7975861
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined vaccine regimen based on parenteral priming with a DNA vaccine and administration of an oral booster consisting of a recombinant Salmonella enterica serovar Typhimurium vaccine strain for immunization against infection with human-derived enterotoxigenic Escherichia coli strains.
    Lásaro MO; Luiz WB; Sbrogio-Almeida ME; Nishimura LS; Guth BE; Ferreira LC
    Infect Immun; 2004 Nov; 72(11):6480-91. PubMed ID: 15501779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of the Shigella flexneri serotype Y (SFL 124) vaccine strain expressing cloned glucosyl transferase gene of converting bacteriophage SfX.
    Huan PT; Taylor R; Lindberg AA; Verma NK
    Microbiol Immunol; 1995; 39(7):467-72. PubMed ID: 8569531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.
    Bârzu S; Arondel J; Guillot S; Sansonetti PJ; Phalipon A
    Infect Immun; 1998 Jan; 66(1):77-82. PubMed ID: 9423842
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterologous expression of Intimin and IpaB fusion protein in Lactococcus lactis and its mucosal delivery elicit protection against pathogenicity of Escherichia coli O157 and Shigella flexneri in a murine model.
    Sagi S; Konduru B; Parida M
    Int Immunopharmacol; 2020 Aug; 85():106617. PubMed ID: 32464569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mucosal immunization of BALB/c mice using enterotoxigenic Escherichia coli colonization factors CFA/I and CS6 administered with and without a mutant heat-labile enterotoxin.
    Byrd W; Cassels FJ
    Vaccine; 2003 May; 21(17-18):1884-93. PubMed ID: 12706673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Co-expression of CFA/I and CS6 of Enterotoxigenic Escherichia coli ( ETEC ) in Shigella flexneri 2a T32 Derivative Strain FWL01].
    Zheng JP; Wang LC; Wang P; Luo G; Li SQ; Duan HQ; Huang CF; Zhang ZS
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Nov; 35(11):1005-10. PubMed ID: 14614538
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Self-experiments with ingestion of various bacteria.
    Rédey B
    Acta Microbiol Acad Sci Hung; 1974; 21(1-2):45-62. PubMed ID: 4216252
    [No Abstract]   [Full Text] [Related]  

  • 56. Outer Membrane Vesicles Derived from
    Tian H; Li B; Xu T; Yu H; Chen J; Yu H; Li S; Zeng L; Huang X; Liu Q
    Appl Environ Microbiol; 2021 Sep; 87(19):e0096821. PubMed ID: 34319809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a.
    Liu Q; Su H; Bian X; Wang S; Kong Q
    Int J Med Microbiol; 2020 Jul; 310(5):151427. PubMed ID: 32654768
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Construction and evaluation of a virG thyA double mutant of Shigella flexneri 2a as a candidate live-attenuated oral vaccine.
    Yoshikawa M; Sasakawa C; Okada N; Takasaka M; Nakayama M; Yoshikawa Y; Kohno A; Danbara H; Nariuchi H; Shimada H
    Vaccine; 1995; 13(15):1436-40. PubMed ID: 8578822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.
    Kotloff KL; Noriega FR; Samandari T; Sztein MB; Losonsky GA; Nataro JP; Picking WD; Barry EM; Levine MM
    Infect Immun; 2000 Mar; 68(3):1034-9. PubMed ID: 10678904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.